Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875710 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL585441 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL4579011 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL98805 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL7515272 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL4580702 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL4579395 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL3986297 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL6561802 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL7523852 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112341572-A | Preparation method of styrene-butadiene latex applied to lithium ion battery cathode | 深圳港池科技有限公司 | 2021-02-09 | — | — | CN | claimed |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-05 | — | — | US | disclosed |
| US-12600725-B2 | Selective GRP94 inhibitors and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20240058482-A1 | USES OF LABELED HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4310084-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | Jinan University (CN) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| CN-116120288-A | hERG potassium channel inhibitor based on IR780 derivative, and preparation method and application thereof | 山东师范大学 | 2023-05-16 | — | — | CN | disclosed |
| US-20230123747-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-04-20 | — | — | US | disclosed |
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2023-03-21 | — | — | US | disclosed |
| EP-0635023-A4 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES. | ISIS PHARMACEUTICALS INC (US) | 1996-03-20 | — | — | EP | disclosed |
| US-5459255-A | For incorporation into oligonucleotides, cleaving RNA site specifically | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| WO-1995021184-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-10 | — | — | WO | disclosed |
| US-5424451-A | Used as cholinesterase activity inhibitors | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1995-06-13 | — | — | US | disclosed |
| WO-1995014707-A1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS, INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0635023-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5302593-A | Aminoalkylcarbamic esters of eseroline suitable for use as chlorinesterase activity inhibitors | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1994-04-12 | — | — | US | disclosed |
| EP-0575954-A1 | Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase acitivity inhibitors and relative preparation process | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1993-12-29 | — | — | EP | disclosed |
| WO-1993018052-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
| US-4610981-A | N-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)-alkyl]benzenesulfonamides and thromboxane synthetase/antihypertensive compositions | AMERICAN CYANAMID COMPANY (US) | 1986-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058482-A1 | USES OF LABELED HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AA1 | TDP1 1372/4885L3MBTL1 1456/4885CHRM2 4885/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | TDP1 1654/4885L3MBTL1 969/4885CHRM2 4861/4885 |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | TDP1 1354/4885L3MBTL1 2391/4885CHRM2 4879/4885 |
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AA1 | TDP1 1372/4885L3MBTL1 1456/4885CHRM2 4885/4885 |
| US-12600725-B2 | Selective GRP94 inhibitors and uses thereof | GRPR, HSPB1, HSP90AB2P | TDP1 3007/4885L3MBTL1 3363/4885CHRM2 2761/4885 |
| US-20230123747-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | HSP90B1, HSP90AB2P, HSPE1 | TDP1 2671/4885L3MBTL1 1838/4885CHRM2 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.